Abstract: A method for detecting a Salmonella species, E. coli O157:H7, or Listeria monocytogenes is disclosed. The method involves amplifying a genomic nucleotide sequence of a corresponding species and detecting the amplification product. Various primers and probes that can be used in the method are also disclosed. In one embodiment, the amplification step of the method is accomplished by real-time PCR and the amplification product is detected by fluorescence resonance energy transfer using a pair of labeled polynucleotides.
Abstract: Single nucleotide polymorphisms (SNPs) in the gene encoding micromolar calcium activated neutral protease (mu-calpain) effect meat tenderness in bovine. These SNPs correspond to position 18 of exon 9 of Seq. ID No. 3, position 17 of exon 14 of Seq. ID No. 4, and position 185 on intron 19 of Seq. ID No. 4, of the CAPN1 gene encoding mu-calpain. Alleles wherein the SNP at position 18 of exon 9 encodes alanine at amino acid 316 of bovine mu-calpain, the SNP at position 17 on exon 14 encodes valine at amino acid 530 of bovine mu-calpain, and the SNP at position 185 on intron 19 is an cytosine, are all indicative of increased meat tenderness. Any one or all of these SNPs may be used as markers for selecting bovines having superior meat tenderness, and selecting animals for breeding purposes.
Type:
Grant
Filed:
December 18, 2003
Date of Patent:
July 3, 2007
Assignee:
The United States of America as represented by the Secretary of Agriculture
Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclaimpsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin ? subunit (hCG-?), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.
Type:
Grant
Filed:
January 16, 2004
Date of Patent:
June 26, 2007
Assignee:
The Chinese University of Hong Kong
Inventors:
Yuk-Ming Dennis Lo, Kai On Ng, Bo Yin Tsui, Wai Kwun Rossa Chiu
Abstract: Methods for the production and use of stable complexes of duplex nucleic acid molecules and oligonucleotides are presented. These complexes can be used for the detection and purification of a known nucleic acid target as well as the manipulation of a defined nucleic acid target sequence.
Type:
Grant
Filed:
September 26, 2003
Date of Patent:
June 12, 2007
Assignee:
University of Delaware
Inventors:
Eric B. Kmiec, Howard B. Gamper, Michael C. Rice, Michael G. Usher
Abstract: The invention provides a method for diagnosing susceptibility of individual cancer (e.g. liver cancer), comprising the steps of detecting individual HC56 gene, transcript and/or protein, and comparing it with normal HC56 gene, transcript and/or protein. The difference show the possibility of individual cancer is higher than that in the normal population. The invention also provides the corresponding detection kit.
Abstract: The invention concerns a method for the diagnosis and/or the follow up of the evolution of cancer comprising the analysis of the RNA components of the telomerase enzyme present in the plasma or serum of the blood.
Type:
Grant
Filed:
May 16, 2001
Date of Patent:
January 16, 2007
Inventors:
Xu Qi Chen, Maurice Stroun, Philippe Anker
Abstract: An isolated nucleic acid containing a human ribonucleotide reductase M2 subunit promoter sequence or genomic sequence. Also disclosed are methods of determining whether a subject is suffering from or at risk for developing a cell proliferation-associated disorder, identifying a compound for treating a cell proliferation-associated disorder, treating a cell proliferation-associated disorder, and developing a procedure for treating a cell proliferation-associated disorder.
Abstract: Detection of variable nucleotide(s) is based on primer extension and incorporation of detectable nucleoside triphosphates. By selecting the detection step primers from the region immediately adjacent to the variable nucleotide, this variation can be detected after incorporation of as few as one nucleoside triphosphate. Labelled nucleoside triphosphates matching the variable nucleotide are added and the incorporation of a label into the detection step primer is measured. The selection of the detection step primer is important to the method according to this invention and is dependent on the nucleotide sequence of interest. The detection step primers are preferably selected so as to span the region immediately toward the 3? end from the variable nucleotide to be detected. The detection step primers can also be complementary to a sequence beginning several nucleotides removed from the variable nucleotide.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
November 7, 2006
Assignee:
Orchid Cellmark Inc.
Inventors:
Hans E. Söderlund, Anne-Christine Syvanen
Abstract: An isolated nucleic acid molecule comprising a nucleotide sequence encoding a transcriptional enhancer of cytochrome P450 (P450) CYP3A4 production or expression is disclosed, as are uses of the nucleic acid molecule for screening compounds for xenobiotic induction of CYP3A4 expression in cells and animals.
Abstract: A minicell display method has been developed which has significant advantages for screening peptide libraries for candidates that can bind and effectively modulate a particular biological process. The method, based on the small, anucleate minicell, has increased versatility in generating unique sequences to screen as well as increasing the size of the peptides to be screened. In vivo mutagenesis, at the level of protein synthesis, as well as DNA replication, increases diversification of the library to be screened and therefore substantially increases the number of potential peptides that can modulate a particular biological response or mechanism.
Abstract: The invention relates to the use of an asthma-associated gene, designated AAGA, the protein molecule encoded by AAGA and related molecules in diagnostic and prognostic screening of patient populations, to polymorphisms in AAGA, and to the use of the protein encoded by AAGA or a variant thereof as a therapeutic target.
Type:
Grant
Filed:
July 12, 2002
Date of Patent:
October 17, 2006
Assignees:
Novartis AG, Wake Forest University Health Sciences, Rijksuniversiteit Groningen
Inventors:
Paul Andrew Whittaker, Deborah Alexis Meyers, Dirkje Sjoukje Postma, Eugene Roland Bleecker
Abstract: The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.
Type:
Grant
Filed:
August 16, 2002
Date of Patent:
October 10, 2006
Assignees:
Regents of the University of Minnesota, The Feinstein Institute for Medical Research
Inventors:
Timothy W. Behrens, Emily C. Baechler, Peter K. Gregersen
Abstract: It is provided isolated polynucleotides that include sequences from genomic region around the gene CD 81. The polynucleotides include polymorphisms associated with treatment response of HCV patients to interferon-? and ribavirin combined therapy and are useful as the probes in screening for patients who will response to interferon-? and ribavirin combined therapy. It is further provided linkage disequilibrium structure of the CD81 gene and haplotype information within a particular LD block, which can be used for prediction of the treatment outcome of the interferon-? and ribavirin combined therapy on HCV patients.
Abstract: The present invention relates to methods and compositions of a novel gene and the peptide encoded by the gene. Mutations in the gene, named atlastin, are factors in the disease Hereditary Spastic Paraplegia and related disorders. The present invention will be used for the in the research, diagnosis and treatment of these disabling diseases.
Abstract: A high-throughput assay for characterizing a subject's genetic makeup is disclosed. Specifically a high-throughput assay utilizing PCR is disclosed that permits the rapid and accurate characterization of a subject's inherited alleles of the polymorphic glutathione S-transferase (GST) genes GSTM1, GSTM3, GSTP1, and GSTT1. This method allows detection of the specific alleles inherited, including the gene dosage of GSTM1 and GSTT1 while not requiring restriction endonuclease digestion of the PCR products in order to detect length differences. Further, the method allows all analyses to be performed simultaneously in the same gel lane, thus further adding efficiency and cost-effectiveness.
Type:
Grant
Filed:
July 20, 2001
Date of Patent:
August 1, 2006
Assignee:
University of Utah Research Foundation
Inventors:
Charles Keller, Linda Ballard, Richard Lemmons, Francis Ali-Osman
Abstract: A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C/C DNA sequence in the 5-HT2A receptor gene. This provides for a method to improve the treatment of an SSRI responsive disorder and in particular depression.
Type:
Grant
Filed:
August 29, 2002
Date of Patent:
August 1, 2006
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The present invention relates to a purified or isolated polynucleotide encoding human CIDE B protein, the regulatory nucleic acids contained therein, polymorphic markers thereof, and the resulting encoded protein, as well as to methods and kits for detecting this polynucleotide and this protein. The present invention also pertains to a polynucleotide carrying the natural regulatory regions of the CIDE B gene which is useful, for example, to express a heterologous nucleic acid in host cells or host organisms as well as functionally active regulatory polynucleotides derived from said regulatory regions.
Abstract: The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
Abstract: A method for determining improved disease resistance in animals is disclosed. The method assays for a novel genetic alleles of the BPI gene of the animal. The alleles are correlated with superior disease resistance. Novel nucleotide sequences, assays and primers are disclosed for the methods of the invention.
Type:
Grant
Filed:
May 31, 2002
Date of Patent:
July 4, 2006
Assignees:
Iowa State University Research Foundation, Inc., Pig Inprovement Company UK Limited, The United States of America as represented by the Secretary of Agriculture
Inventors:
Christopher K. Tuggle, Thomas J. Stabel, Xianwei Shi, Martha A. Mellencamp
Abstract: This invention is related to novel probes, probe sets, methods and kits pertaining to the detection, identification and/or quantitation of yeasts and particularly Dekkera bruxellensis (a.k.a. Brettanomyces) an organism that spoils wine. Preferred probes for the detection of one or more species of the Dekkera/Brettanomyces genus comprise a probing nucleobase sequence, at least a portion of which is selected from the group consisting of: AGC-GGG-TCT-ATT-AGA (Seq. ID No. 1); CCA-GGT-GAG-GGT-CGC (Seq. ID No. 2); CGG-TTG-CCC-GAT-TTC (Seq. ID No. 3); TCG-CCT-TCC-TCC-TCT (Seq. ID No. 4); CGG-TCT-CCA-GCG-ATT (Seq. ID No. 5); CAC-AAG-ATG-TCC-GCG (Seq. ID No. 6); GCG-GGC-ACT-AAT-TGA (Seq. ID No. 7); CAT-CCA-CGA-GGA-ACG (Seq. ID No. 8); GTG-TAA-ACC-AGG-TGC (Seq. ID No. 9); ATG-GCT-CCC-AGA-ACC (Seq. ID No. 10) and GAC-AGA-ATC-GAA-GGG (Seq. ID No. 11).
Type:
Grant
Filed:
June 14, 2000
Date of Patent:
June 13, 2006
Assignee:
Applera Corporation
Inventors:
Jens J. Hyldig-Nielsen, Heather P. O'Keefe, Henrik Stender